Dose the first patient in the Phase 2b study of AG-946
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 8 Jan 2024
- Due
- 30 Jun 2024
- Checked
- 25 Sep 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Dose first patient in Phase 2b study of AG-946 (mid-year)”
What we found
Evidence strength A What the grades mean
The company listed the Phase 2b study initiation as an upcoming milestone in an August 2024 filing, and later confirmed initiation occurred in the third quarter of 2024, after the mid-year deadline.
-
A Agios Pharmaceuticals, Inc. 8-K filed 2024-08-01
“Agios expects to execute on the following additional key milestones and priorities by the end of 2024: ... Lower-risk Myelodysplastic Syndromes: Dose first patient in Phase 2b study of tebapivat (AG-946) (mid-year).” ✓ confirmed on the page
-
A Agios Pharmaceuticals, Inc. 10-Q filed 2024-10-31
“we plan to increase the dosage levels evaluated in the upcoming Phase 2b trial, which we initiated in the third quarter of 2024.” ✓ confirmed on the page
Market reaction: the shares moved -2.1% against the S&P 500 over the three sessions around the disclosure (31 Jul 2024 to 5 Aug 2024). What this measures
Checked 25 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Agios Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-AGIO-000008 · Corrections policy